FDA Rejects Disc Medicine's Bitopertin Despite Fast-Track Review Under New Voucher Program
Feb 14, 2026
The FDA rejected Disc Medicine's bitopertin for erythropoietic protoporphyria, citing uncertainties about clinical benefit despite the drug receiving a priority review voucher. The company will pursue traditional approval with Phase 3 data expected in late 2026.